Merrick M V, Eastwood M A, Anderson J R, Ross H M
J Nucl Med. 1982 Feb;23(2):126-30.
A conjugated bile acid, 23-selena-25-homotaurocholic acid (SeHCAT), labeled with the gamma emitter Se-75, has been evaluated in man. Absorption and excretion were compared with that of simultaneously administered [23-14C]cholic acid. SeHCAT is absorbed quantitatively following oral administration, secreted into the bile at the same rate as cholic acid, reabsorbed from the small intestine, and resecreted. It is not absorbed when the terminal ileum has been excised or bypassed. SeHCAT is therefore the first of a new class of radiopharmaceuticals, namely, gamma-emitting tracers of the complete cycle of the enterohepatic circulation. Its use will simplify investigation of the functional state of the terminal ileum by eliminating the need to collect and process feces.
一种用γ发射体硒-75标记的结合型胆汁酸，即23-硒-25-高牛磺胆酸（SeHCAT），已在人体中进行了评估。将其吸收和排泄情况与同时给予的[23-14C]胆酸进行了比较。口服后，SeHCAT可被定量吸收，以与胆酸相同的速率分泌到胆汁中，从小肠重吸收并再次分泌。当回肠末端被切除或绕过则不会被吸收。因此，SeHCAT是一类新型放射性药物中的首个药物，即肠肝循环完整周期的γ发射示踪剂。它的使用将通过无需收集和处理粪便来简化对回肠末端功能状态的研究。
